HELP votes Wednesday on Overton as FDA shelves CNPV
FDA shelved the CNPV program as HELP set a Wednesday vote on Heidi Overton, while the agency ordered GLP-1 labeling changes, approved two drugs and widened safety actions.
TAG T-7549 · 849 words on the filing

Summary of findings
- FDA shelved the CNPV program as HELP prepares for a Wednesday vote on Heidi Overton.
- FDA required GLP-1 labeling changes for a potential increased risk of rare NAION vision loss.
- Sunharbo became the first FDA-approved factor XIa inhibitor; Pimjetmi also received approval.
- FDA's Zolgensma review found malignancy signals, including confirmed GLI1-linked insertional oncogenesis.
- Cardinal Health's BD Alaris Pump infusion-set recall moved to class I.
The FDA has shelved the Commissioner's National Priority Voucher (CNPV) program, which the Trump administration promoted as a way to speed selected drugs to market, as the Senate Health, Education, Labor and Pensions Committee prepares to vote Wednesday on President Donald Trump's pick for commissioner, Heidi Overton.
If the committee vote passes, her nomination moves to the full Senate for confirmation. Several key Republican senators, including outgoing committee chair Bill Cassidy (R-LA), have said they have not decided whether to support her.
Politico reported that acting FDA Commissioner Kyle Diamantas is expected to leave the administration at the end of the year. An unnamed source said that, if Overton is not confirmed, the administration may ask Sara Brenner, a former acting commissioner, to return in an acting capacity.
Reuters, citing anonymous sources, reported the CNPV shelving. Former FDA Commissioner Marty Makary created the program, which the Trump administration promoted as a way to significantly speed drugs to market that address specific national priorities.
Critics questioned its legality and said it could give preferential treatment to drugmakers that comply with President Donald Trump's demands.
What does this change for drug developers?
Among developers, the practical change is that CNPV no longer offers a stated policy route to faster market access while the program is shelved. Reuters did not report a restart date, revised eligibility criteria or an implementation schedule.
A new GLP-1 label requirement
FDA separately required a safety labeling change for glucagon-like peptide-1 (GLP-1) receptor agonists, warning of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). FDA said the rare condition can cause acute, painless vision loss in one eye and may progress to permanent vision loss. These diabetes drugs have also become popular for weight loss.
Two approvals widen the treatment menu
- FDA approved Bayer's Sunharbo (asundexian) as the first factor XIa inhibitor to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), in combination with antiplatelet therapy. It received fast-track and priority review.
- EMD Serono's Pimjetmi (pimicotinib) won approval for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The drug received fast-track and breakthrough therapy designation.
Diagnostics and fee enforcement
FDA finalized guidance on validating certain in vitro diagnostics for emerging pathogens during a public health emergency. The document details the recommended test data and information sponsors should submit with pre-Emergency Use Authorization submissions.
FDA also published updated over-the-counter Monograph Drug User Fee Program (OMUFA) arrears and paid-facilities lists. The agency named almost 80 pages' worth of facilities that have not paid their OMUFA fees.
Safety signals and field actions
- FDA's review of postmarket adverse-event reports found safety signals involving malignancies in some patients treated for spinal muscular atrophy with Novartis' intravenous infusion, adeno-associated virus (AAV) vector-based gene therapy Zolgensma (onasemnogene abeparvovec). Confirmed reports included product-related insertional oncogenesis involving the GLI1 (Glioma-Associated Oncogene Homolog 1) gene.
- FDA continues to investigate. Despite the tumor risks associated with Zolgensma and Itvisma, its intrathecal-injection version, FDA said, “the benefits of the treatments continue to outweigh their risks for their approved uses.”
- Eugenia US recalled vials of vancomycin hydrochloride after glass particulates were found in the injections. The company notified distributors and customers and warned that the particulates may cause life-threatening embolisms.
- FDA issued an early alert for Intersurgical's 22 mm smoothbore breathing tubes and systems after a manufacturing error caused soft connectors on some products to disconnect from the tubes. Loss of ventilation could cause serious adverse events, including brain damage and death. Intersurgical sent customers letters directing them to remove certain lots from use.
- FDA also warned about Arrow International products containing the Spring Wire Guide after quality issues could cause the hydraulic coating to break apart and enter a patient's bloodstream, leading to life-threatening embolisms. Arrow, a Teleflex subsidiary, sent customers lists of products to remove from shelves.
- FDA upgraded the recall of Cardinal Health presource packs containing BD Alaris Pump infusion sets to a class I recall, following an early alert last month. Some Alaris Pumps have underperformed in a way that could be life-threatening, and Cardinal Health sent updated handling instructions.
Device policy shifts
The Center for Devices and Radiological Health published a discussion paper on evaluating the benefits and risks of robotic medical devices with autonomous or remote teleoperation capabilities. FDA said the paper is intended to promote early, open dialogue on terminology and risk mitigation.
FDA also proposed reclassifying immunohistochemistry test systems indicated for use with a corresponding approved oncology therapeutic product from class III to class II with special controls. Proposed mitigation measures include design verifications and validations needed to satisfy those controls.
For sponsors and device teams, the immediate agenda is concrete: update GLP-1 labeling, execute the named recalls and field actions, and plan around two new approvals rather than a revived CNPV pathway.
via Regulatory Focus (Google News) (Source)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- E-5590
- P-6323
- E-4696
- K-1653
- K-6477